Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel vs Irinotecan in Second-Line Gastric Cancer
NCT01224652Phase 3Unknown
- Sponsor
- Korean Cancer Study Group
- Modality
- Small Molecules, Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of Paclitaxel Micelles for Injection, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in gastric cancer (GC), sponsored by Korean Cancer Study Group. Status: unknown.
02
Drugs
Paclitaxel Micelles for Injectionirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01224652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01224652.